Thanks and welcome, everyone, to today's earnings call. As mentioned, I have our CFO, Agneta Palmér, with me today. And in the conference call today, we'll go through our performance and some highlights in the third quarter before opening up for the customary Q&A. So let's move to page number two right away, please.
So we start looking at the development of some of our longer-term strategic KPIs. We continue to track clearly in line with our plan to increase the share of sales from recurring revenue. Accelerating the share of sales from high-margin products like, for example, our offerings in the BetteBags and Sterile Transfer, which have both had a very strong year so far. And all these activities are, of course, supported by solid and effective quality processes as well. So if we look at sales from recurring revenue, it continues to make up about two-thirds of our sales and the high-margin products are at 70% as of Q3. And when it comes to quality, the number of field actions in relation to sales has decreased significantly in the last three years. We are currently tracking slightly above last year's level, but remain within our expected range on this KPI. These improvements should, of course, be achieved also through responsible financial leverage and an attractive long-term return on invested capital.
Let's move to page number three, please.
So if we look at the key takeaways when it comes to the third quarter and with an emphasis on the financial KPIs overall, we delivered a healthy financial performance in the quarter with top-line growth. Net sales grew 2.1% organically with positive development in most of the business areas. Order intake increased by 2.6% organically. If we then look at the adjusted gross and EBITA margins. They were up in the quarter as a result of the continued positive underlying performance that we've seen for quite a while now. Margins were also supported by a remaining tariff refund of 45 million Swedish kronor. This led to another quarter with strong cash flow and a very solid financial position. Our financial leverage is at 1.5 right now, so well below the 2.5 times EBITDA internal threshold that we have. We have an internal threshold. So let's move to page number four and talk about some of the key events from the quarter. I think, first and foremost, I would like to share the information that we recently received regarding the results of our annual customer feedback survey. And I am very pleased to report that our Net Promoter Score has reached an all-time high. We also had very strong employee engagement, and these are two KPIs that are extremely important for long-term success. I'm also happy to say that we, at the end of the quarter, initiated the launch of the new version of our platform Cardiohelp II in CEE countries and in Hong Kong. And so far, this has been very well received by our customers. We look forward to continuing this launch, and within our digital health solutions, we launched Torin Plan Optimizer, which supports surgical planning in hospitals thanks to an AI-powered system. And just to quote the management at Klinikum Stuttgart in Germany, he mentioned that this supports better informed planning decisions and much more effective use of our existing surgical capacity. Furthermore, in collaboration with the Swedish non-profit organization, Lifted, we continued our support to the National Specialized Children’s Hospital Okhmatdyt in Kyiv through a donation of ECMO consumables. The hospital operates one of Ukraine's leading pediatric ECMO programs, treating critically ill children from across the country. And in 2025, the hospital reported that it doubled its ECMO capacity and this continues to trend in a good direction. We are very happy to be part of supporting this important initiative. It is really clear that our donation helps sustain life-saving capability. And then, just continuing on the pediatric track for a moment. We also received 510(k) clearance in the quarter for a new, smaller Edi catheter, which is used with our ventilators. And this makes it possible to support premature infants between 500 and 1,000 grams in weight. It is also very comforting to see that our sustainability KPIs are tracking well. Just to highlight two of them, compared to last year, we have reduced our scope 1 and 2 greenhouse gas emissions by more than 20%, and the share of renewable energy is above 70%. We can then move to page number five, please. So if we talk about our organic top-line growth, this was driven by Acute Care Therapies, Life Science, and Surgical Workflows in the quarter. So order intake grew 2.6% organically. The organic order intake in Acute Care Therapies increased primarily in ECLS therapy consumables and cardiac assist consumables. Life Sciences organic order intake declined slightly during the quarter. The positive performance in bioprocessing and service did not fully offset the continuing decline that we see within our washer-isolator and sterilizer subsegment. Surgical workflows increased, mainly driven by strong performance in operating room equipment such as surgical tables and lights. We then look at the net sales. We grew net sales by 2.1% in the quarter. This was mainly driven by disciplined work with pricing. With pricing, Acute Care Therapies increased net sales organically, primarily due to ECLS therapy consumables, intra-aortic balloon pumps and cardiac assist, and also our covered stents. Organic net sales for Life Science fell slightly following a continuing decline in washers, isolators, and sterilizers, and this was despite robust growth in sterile transfer in Surgical Workflows. Organic net sales rose slightly following growth in infection control and in our digital health solutions portfolio. We can then move to page number six, please. And I hand over to you for a moment.